当前位置： SCI文献检索 > JOURNAL OF VIRAL HEPATITIS期刊下所有文献 > Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.

Abstract：

:Anaemia during peginterferon (PEG-IFN) and ribavirin (RBV) therapy is common in human immunodeficiency virus/hepatitis C virus (HIV/HCV)-coinfected patients despite the use of lower doses of RBV than are recommended for HIV-seronegative persons. In addition, concurrent zidovudine (ZDV) may exacerbate the anaemia caused by PEG-IFN and RBV. We retrospectively analysed the incidence of anaemia, RBV dose reduction and epoetin-alpha (EPO) use among coinfected patients treated with PEG-IFN and weight-based RBV (800-1400 mg/day) who enrolled in two clinical trials and had haemoglobin (Hb) levels assessed at baseline and after 4 and/or 12 weeks of HCV treatment. Overall, 217 patients were included; pre-treatment Hb levels (mean 14.7 g/dL) were similar in all patients, including ZDV users (29% of patients). After 4 weeks of therapy, the mean Hb decline was greater among ZDV recipients (3.13 g/dL) compared with those on other anti-retroviral treatment (ART) (2.13 g/dL) or on no ART (1.47 g/dL) (P < 0.0001). RBV dose reduction and EPO use were more common in patients taking ZDV compared with those not taking ZDV (P < 0.0001). RBV dose was not associated with Hb reduction, RBV dose reduction or EPO use. Virologic response after 12 weeks of therapy and the treatment discontinuation rate did not differ by ZDV use. The use of ZDV but not weight-based RBV dosing was associated with an increased risk of anaemia, RBV dose reduction or EPO use in coinfected patients treated with PEG-IFN/RBV. However, ZDV use was not associated with higher rates of treatment discontinuation or lower early virologic response rates. HIV and hepatitis C care providers should be cognizant of these data.

journal_name

J Viral Hepat

journal_title

Journal of viral hepatitis

authors

Alvarez D,Dieterich DT,Brau N,Moorehead L,Ball L,Sulkowski MS

doi

10.1111/j.1365-2893.2006.00749.x

subject

Has Abstract

pub_date

2006-10-01 00:00:00

pages

683-9

issue

10

eissn

1352-0504

issn

1365-2893

pii

JVH749

journal_volume

13

pub_type

杂志文章,随机对照试验

相关文献

JOURNAL OF VIRAL HEPATITIS文献大全
  • HCV burden of infection in Egypt: results from a nationwide survey.

    abstract：:Egypt is the country with the largest hepatitis C virus (HCV) epidemic in the world. In 2008, a Demographic Health Survey (DHS) was carried out in Egypt, providing for the first time a unique opportunity for HCV antibody testing on a nationwide representative sample of individuals. Consenting individuals answered a qu...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2011.01576.x

    authors： Guerra J,Garenne M,Mohamed MK,Fontanet A

    更新日期：2012-08-01 00:00:00

  • The large form of ADAR 1 is responsible for enhanced hepatitis delta virus RNA editing in interferon-alpha-stimulated host cells.

    abstract：:Hepatitis delta virus (HDV) RNA editing controls the formation of hepatitis-delta-antigen-S and -L and therefore indirectly regulates HDV replication. Editing is thought to be catalysed by the adenosine deaminase acting on RNA1 (ADAR1) of which two different forms exist, interferon (IFN)-alpha-inducible ADAR1-L and co...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2005.00663.x

    authors： Hartwig D,Schütte C,Warnecke J,Dorn I,Hennig H,Kirchner H,Schlenke P

    更新日期：2006-03-01 00:00:00

  • Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

    abstract：:Chronic hepatitis C infection leads to increased hepatocyte apoptosis. Because engulfment of apoptotic bodies (ABs) by hepatic stellate cells (HSC) is profibrogenic, we compared the effects of ABs derived from hepatitis C virus (HCV)-negative vs HCV-infected (Con1+) Huh7 hepatoblastoma cells on fibrogenic and activati...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2010.01362.x

    authors： Gieseler RK,Marquitan G,Schlattjan M,Sowa JP,Bechmann LP,Timm J,Roggendorf M,Gerken G,Friedman SL,Canbay A

    更新日期：2011-11-01 00:00:00

  • Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

    abstract：:Improved understanding of natural history of hepatitis C virus (HCV) RNA levels in chronic infection provides enhanced insights into immunopathogenesis of HCV and has implications for the clinical management of chronic HCV infection. This study assessed factors associated with HCV RNA levels during early chronic infec...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12384

    authors： Hajarizadeh B,Grady B,Page K,Kim AY,McGovern BH,Cox AL,Rice TM,Sacks-Davis R,Bruneau J,Morris M,Amin J,Schinkel J,Applegate T,Maher L,Hellard M,Lloyd AR,Prins M,Geskus RB,Dore GJ,Grebely J,InC3 Study Group.

    更新日期：2015-09-01 00:00:00

  • Early viral clearance and sustained response in chronic hepatitis C: a controlled trial of interferon and ribavirin after high-dose interferon induction.

    abstract：:High-dose induction with alpha-interferon induces early viral clearance of hepatitis C and combined with ribavirin enhances sustained response. We assess whether adding ribavirin after viral clearance obtained by alpha-interferon induction increased the rate of viral eradication.Forty-one naïve patients with chronic h...

    journal_title：Journal of viral hepatitis

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2893.2002.00370.x

    authors： Di Marco V,Ferraro D,Almasio P,Vaccaro A,Parisi P,Cappello M,Cino N,Di Stefano R,Craxì A

    更新日期：2002-09-01 00:00:00

  • Methodological issues in papers on IFN therapy: time for reappraisal.

    abstract：:We conducted an analytical review of 194 full papers on interferon (IFN) therapy for chronic hepatitis C to evaluate current methodology (i.e. study design, criteria for evaluating the efficacy of therapy and predictors of response). Of the papers evaluated, 64 were randomized controlled trials (RCT), 40 were non-rand...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2893.2000.00214.x

    authors： Kondili LA,Taliani G,Tosti ME,De Bac C,Pasquazzi C,Mele A

    更新日期：2000-05-01 00:00:00

  • Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.

    abstract：:The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyse whether the use of LDV/SOF treatment is associated with a new occurrence of hepa...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.13075

    authors： Idilman R,Demir M,Aladag M,Erol C,Cavus B,Iliaz R,Koklu H,Cakaloglu Y,Sahin M,Ersoz G,Koksal İ,Karasu Z,Ozgenel M,Turan İ,Gunduz F,Ataseven H,Akdogan M,Kiyici M,Koksal AS,Akhan S,Gunsar F,Tabak F,Kaymakoglu S

    更新日期：2019-06-01 00:00:00

  • The association of HIV viral load with indirect markers of liver injury.

    abstract：:This study assessed the association of HIV RNA with indirect markers of liver injury including FIB-4 index, liver enzymes and platelet counts in a high-risk Hispanic population. The data were derived from a prospective study that included 138 HIV/hepatitis C (HCV)-coinfected and 68 HIV-infected participants without he...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2011.01529.x

    authors： Forrester JE,Rhee MS,McGovern BH,Sterling RK,Knox TA,Terrin N

    更新日期：2012-02-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

    abstract：:We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2893.2006.00768.x

    authors： Abergel A,Hezode C,Leroy V,Barange K,Bronowicki JP,Tran A,Alric L,Castera L,Bernard PH,Henquell C,Lafeuille H,Ughetto S,Darcha C,Chevallier M,Martineau N,Dubost S,Randl K,Dhumeaux D,Bommelaer G,Bonny C,French mult

    更新日期：2006-12-01 00:00:00

  • In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.

    abstract：:DNA-based vaccination appears of promise for chronic hepatitis B immunotherapy, although there is an urgent need to increase its efficacy. In this preclinical study, we evaluated the therapeutic benefit of cytokine (IL-2, IFN-γ) genes co-delivery with DNA vaccine targeting hepadnaviral proteins in the chronic duck hep...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12023

    authors： Saade F,Buronfosse T,Guerret S,Pradat P,Chevallier M,Zoulim F,Jamard C,Cova L

    更新日期：2013-04-01 00:00:00

  • Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.

    abstract：:Socio-demographic and behavioural characteristics are associated with delayed diagnosis and disease progression in HCV-infected persons. However, many analyses focused on single variables rather than groups defined by several variables. We used latent class analysis to study all 4488 persons enrolled in the Swiss Hepa...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12535

    authors： Giudici F,Bertisch B,Negro F,Stirnimann G,Müllhaupt B,Moradpour D,Cerny A,Keiser O,Swiss Hepatitis C Cohort Study.

    更新日期：2016-09-01 00:00:00

  • Safety and efficacy of coblopasvir and sofosbuvir in patients with genotypes 1, 2, 3 and 6 HCV infections without or with compensated cirrhosis.

    abstract：:A simple, pangenotypic and effective treatment regimen for patients with a broad range of chronic hepatitis C virus (HCV) infections remains an unmet medical need. We conducted a phase 2, randomized, open study involving untreated patients with chronic HCV genotypes 1, 2, 3, or 6 infections. Patients without cirrhosis...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.13208

    authors： Rao H,Song G,Li G,Yang Y,Wu X,Guan Y,Mao Q,Jiang X,Wang C,Zhang Y,Jia J,Guo X,Li C,Ning J,Qin H,Pan H,Wei L

    更新日期：2020-01-01 00:00:00

  • Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B.

    abstract：:Controversial results have been reported concerning the correlation between serum levels of IgM antibodies to hepatitis B core antigen (IgM HBcAb) and the histological activity of chronic hepatitis B. In this study, paired serum samples and liver biopsies were collected from 200 consecutive chronic hepatitis B patient...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1046/j.1365-2893.1999.00171.x

    authors： Colloredo G,Bellati G,Sonzogni A,Zavaglia C,Fracassetti O,Leandro G,Ghislandi R,Minola E,Ideo G

    更新日期：1999-11-01 00:00:00

  • Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response.

    abstract：:It is unclear whether the achievement of virologic response modifies the risk of hepatocellular carcinoma (HCC) differently in chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Our aim was to compare the risk of HCC between patients with CHB and CHC who achieved virological response. We analysed data from patie...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12723

    authors： Kim GA,Han S,Kim HD,An J,Lim YS

    更新日期：2017-11-01 00:00:00

  • Enhanced antiviral effect in cell culture of type 1 interferon and ribozymes targeting HCV RNA.

    abstract：:We have recently shown that the replication of an HCV-poliovirus (PV) chimera that is dependent upon the hepatitis C virus (HCV) 5' untranslated region (UTR) can be inhibited by treatment with ribozymes targeting HCV RNA. To determine the antiviral effects of anti-HCV ribozyme treatment in combination with type 1 inte...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1046/j.1365-2893.2001.00321.x

    authors： Macejak DG,Jensen KL,Pavco PA,Phipps KM,Heinz BA,Colacino JM,Blatt LM

    更新日期：2001-11-01 00:00:00

  • Virological efficacy of combination therapy with corticosteroid and nucleoside analogue for severe acute exacerbation of chronic hepatitis B.

    abstract：:The short-term prognosis of patients with severe acute exacerbation of chronic hepatitis B (CHB) leading to acute liver failure is extremely poor. We have reported the efficacy of corticosteroid in combination with nucleoside analogue in the early stages, but virological efficacy has not been documented. Our aim was t...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12258

    authors： Yasui S,Fujiwara K,Nakamura M,Miyamura T,Yonemitsu Y,Mikata R,Arai M,Kanda T,Imazeki F,Oda S,Yokosuka O

    更新日期：2015-02-01 00:00:00

  • Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.

    abstract：:Sustained virologic response (SVR) is the standard measure for evaluating response to therapy in patients with chronic hepatitis C (CHC). The aim of this study was to prospectively assess the durability of SVR in the pivotal studies of peginterferon (PEG-IFN) α-2b or IFN α-2b. We conducted two phase 3b long-term follo...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/jvh.12074

    authors： Manns MP,Pockros PJ,Norkrans G,Smith CI,Morgan TR,Häussinger D,Shiffman ML,Hadziyannis SJ,Schmidt WN,Jacobson IM,Bárcena R,Schiff ER,Shaikh OS,Bacon B,Marcellin P,Deng W,Esteban-Mur R,Poynard T,Pedicone LD,Brass CA

    更新日期：2013-08-01 00:00:00

  • Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.

    abstract：:Response to interferon-alpha (IFN-alpha) treatment in hepatitis C is poorer when cirrhosis is present. In the third Australian multicentre hepatitis C trial, Aushep-3, we examined the efficacy and tolerability of an intensive 24-week course of interferon-alpha 2a in Child-Pugh grade A patients with chronic hepatitis C...

    journal_title：Journal of viral hepatitis

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1046/j.1365-2893.1997.00062.x

    authors： Farrell G,Cooksley WG,Dudley FJ,Watson K

    更新日期：1997-09-01 00:00:00

  • Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients.

    abstract：:Transient elastometry (TE) could provide a more accurate evaluation of the frequency and risk factors of liver fibrosis in hepatitis C virus (HCV) infection than that based on biopsy. The aim of this study was to assess the prevalence of and factors associated with significant liver fibrosis in a large population of H...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2893.2009.01229.x

    authors： Pineda JA,González J,Ortega E,Tural C,Macías J,Griffa L,Burgos A,Grafihco Study Team.

    更新日期：2010-10-01 00:00:00

  • Molecular and serological characterization of hepatitis B virus in deferred Ghanaian blood donors with and without elevated alanine aminotransferase.

    abstract：:Candidate blood donors in Ghana are frequent carriers of hepatitis B virus (HBV). A comparative study of 117 donor samples including 46 with alanine aminotransferase (ALT) > or = 60 IU/L and 71 with < or =40 IU/L level was undertaken. S and the basic core promoter-precore regions (BCP/PC) sequencing was used to identi...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2006.00741.x

    authors： Candotti D,Opare-Sem O,Rezvan H,Sarkodie F,Allain JP

    更新日期：2006-11-01 00:00:00

  • Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.

    abstract：:The aim of this study was to evaluate the pharmacokinetic profile of daclatasvir (DCV) and asunaprevir (ASV) dual therapy in haemodialysis patients infected with hepatitis C virus (HCV). Eighteen haemodialysis patients and 54 patients with normal renal function were treated with DCV and ASV dual therapy for 24 weeks. ...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,多中心研究

    doi：10.1111/jvh.12553

    authors： Kawakami Y,Imamura M,Ikeda H,Suzuki M,Arataki K,Moriishi M,Mori N,Kokoroishi K,Katamura Y,Ezaki T,Ueno T,Ide K,Masaki T,Ohdan H,Chayama K

    更新日期：2016-11-01 00:00:00

  • The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes.

    abstract：:Hepatocellular carcinoma (HCC) is the most common complication of HCV infection leading to liver transplantation. We evaluated the impact of aetiology of liver disease on patient and graft survival following liver transplantation for HCC. From the Scientific Registry of Transplant Recipients (2002-2011), all adults wh...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12449

    authors： Younossi ZM,Stepanova M,Saab S,Ahmed A,Lam B,Srishord M,Venkatesan C,Wai H,Henry L

    更新日期：2016-01-01 00:00:00

  • High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

    abstract：:To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe p...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.13035

    authors： Schulkind J,Stephens B,Ahmad F,Johnston L,Hutchinson S,Thain D,Ward Z,Vickerman P,Hickman M,Dillon JF

    更新日期：2019-05-01 00:00:00

  • Altered balance between collagen formation and degradation after successful direct-acting antiviral therapy of chronic hepatitis C.

    abstract：:The effect of direct-acting antiviral (DAA) therapy on extracellular matrix (ECM) turnover, a prominent feature of chronic hepatitis C (CHC), is unknown. ECM protein degradation and formation generate fragments reflecting the tissue turnover balance when quantified in the blood. PRO-C3 and PRO-C4 reflect type III and ...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.13416

    authors： Laursen TL,Villesen IF,Leeming DJ,Karsdal MA,Sølund C,Tarp B,Kristensen LH,Holmboe CH,Leutscher P,Laursen AL,Gudmann NS,Grønbaek H

    更新日期：2021-02-01 00:00:00

  • Telbivudine treatment is associated with high hepatitis B e antigen seroconversion and immune modulatory effects in chronic hepatitis B patients.

    abstract：:Chronic hepatitis B (CHB) is characterized by an impaired immune response to hepatitis B virus. Among the nucleos(t)ides used in CHB treatment, telbivudine is associated with the highest rates of hepatitis B e antigen (HBeAg) seroconversion rates, which are similar to those observed with pegylated interferon (PegIFN)....

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,评审

    doi：10.1111/jvh.12059

    authors： Wang GQ,Ding YP,Dong YH

    更新日期：2013-04-01 00:00:00

  • Increased intrahepatic and circulating levels of endoglin, a TGF-beta1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis.

    abstract：:Endoglin, a transforming growth factor (TGF)-beta1 co-receptor, has been associated with renal and cutaneous fibrosis, as overexpression of this protein has been observed in biopsies from patients with glomerulosclerosis and scleroderma, respectively. Our aim was to evaluate whether endoglin may be associated with hep...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2006.00733.x

    authors： Clemente M,Núñez O,Lorente R,Rincón D,Matilla A,Salcedo M,Catalina MV,Ripoll C,Iacono OL,Bañares R,Clemente G,García-Monzón C

    更新日期：2006-09-01 00:00:00

  • The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia.

    abstract：:Treating chronic hepatitis C with pegylated interferon alpha may induce or exacerbate psychiatric illness including depression, mania and aggressive behaviour. There is limited data regarding treatment in the context of chronic schizophrenia. We sought to establish the safety and efficacy of treating patients with sch...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.12234

    authors： Mustafa MZ,Schofield J,Mills PR,Priest M,Fox R,Datta S,Morris J,Forrest EH,Gillespie R,Stanley AJ,Barclay ST

    更新日期：2014-07-01 00:00:00

  • Viral load change and sequential evolution of entire hepatitis C virus genome in Irish recipients of single source-contaminated anti-D immunoglobulin*.

    abstract：:In hepatitis C virus (HCV) infection, serum viral load is important in the prediction of therapeutic efficacy. However, factors that affect the viral load remain poorly understood. To identify viral genomic elements responsible for the viral load, we investigated samples from a population of Irish women who were iatro...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/j.1365-2893.2005.00645.x

    authors： Itakura J,Nagayama K,Enomoto N,Hamano K,Sakamoto N,Fanning LJ,Kenny-Walsh E,Shanahan F,Watanabe M

    更新日期：2005-11-01 00:00:00

  • Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis.

    abstract：:Patients with chronic hepatitis B (HBsAg-positive) are at risk of viral reactivation if rituximab is administered without antiviral treatment, a potentially fatal complication of treatment. Patients with so-called 'resolved hepatitis B virus infection' (HBsAg-negative/cAb-positive) may also be at risk. We performed a ...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章,meta分析,评审

    doi：10.1111/jvh.12402

    authors： Mozessohn L,Chan KK,Feld JJ,Hicks LK

    更新日期：2015-10-01 00:00:00

  • Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy/ablation.

    abstract：:Antiviral therapy has been shown to improve the prognosis of hepatitis B virus (HBV) DNA-positive hepatocellular carcinoma (HCC) after radical treatment, but antiviral treatments require further optimization. This study aimed to evaluate the efficacies of different antiviral strategies with HCC patients after hepatect...

    journal_title：Journal of viral hepatitis

    pub_type： 杂志文章

    doi：10.1111/jvh.13236

    authors： Qi W,Zhang Q,Xu Y,Wang X,Yu F,Zhang Y,Zhao P,Guo H,Zhou C,Wang Z,Sun Y,Liu L,Xuan W,Wang J

    更新日期：2020-04-01 00:00:00